“Optimizing the Treatment Sequence: The Cumulative Clinical Benefit of Treatment Initiation With Deucravacitinib Versus Apremilast over 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis from the POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 6, Nov. 2022, p. s62, https://doi.org/10.25251/skin.6.supp.62.